Medical device IPOs garner investor attention

Greetings,

There continues to be exciting news within the medical device industry. Recently, electroCore (NASDAQ: ECOR), a bioelectronic medicine company which commercializes a handheld nerve stimulation device, specifically for the treatment of migraines, completed their initial public offering on June 22. Originally priced at $15 per share, the company's stock opened up with a trade of $19 a share, presenting a +27.3% increase from the pricing of the deal.

On June 28th, Neuronetics (NASDAQ: STIM), a medical technology company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the pricing of its IPO. The Company raised $94 million by offering 5.5 million shares at $17.

The launch of these companies provides additional proof of the current interest of investors in the bioelectronic arena. We strongly believe that bioelectronic medicine is the most promising and innovative field of medicine, that has already attracted high-profile investors such as Alphabet (NASDAQ: GOOG), Apple Inc. (NASDAQ: APPL), and IBM Watson (NYSE: IBM).

Like many medical devices, these companies obtained 510(k) clearance of their devices. BioSig is seeking to get FDA clearance on our PURE EP™ System through the same route, yet holds a larger market of approximately 6.5 million Americans, who suffer from either atrial fibrillation or ventricular tachycardia.

These Initial Public Offerings combined with the recent acquisition of EPD Solutions by Royal Philips serve as an indicator that Wall Street is truly taking notice of the vast potential within the biomedical technology and medical device markets. With a sharp jump above the original price of the deal it appears as if individual and retail investors are also bullish on the space.

As the medtech space continues to heat up, it is easy to see why management remains optimistic about our future.

Operating in an underserved market that historically lacked innovation, we hope that BioSig's Pure EP™ System can become the answer for healthcare professionals requiring clearer signals and more accurate readings. With a growing interest of investors in the biomedical technology space, BioSig will strive for a strong impact through our innovative technology.

If you have any questions about the content of this post, or would like to speak to our Investor Relations team, please get in touch with us on info@biosigtech.com.

Kind Regards,

Ken Londoner

Chairman & CEO
BioSig Technologies, Inc.

Return to Listings